MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jensen, L. H.
Right arrow Articles by Jensen, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jensen, L. H.
Right arrow Articles by Jensen, P. B.

Vol. 61, Issue 5, 1235-1243, May 2002

Maleimide Is a Potent Inhibitor of Topoisomerase II in Vitro and in Vivo: A New Mode of Catalytic Inhibition

Lars H. Jensen, Axelle Renodon-Corniere, Irene Wessel, Seppo W. Langer, Birgitte Søkilde, Elisabeth V. Carstensen, Maxwell Sehested, and Peter B. Jensen

Laboratory for Experimental Medical Oncology, Finsen Center, Copenhagen, Denmark (L.H.J., S.W.L., P.B.J.); Department of Pathology, Laboratory Center, Copenhagen, Denmark (L.H.J., A.-R.C., I.W., M.S.); and Topo Target A/S, Copenhagen, Denmark (L.H.J., I.W., S.W.L., B.S., E.V.C., M.S., P.B.J.)

Maleimide, N-ethyl-maleimide (NEM), and N-methyl-maleimide (NMM) were identified as potent catalytic inhibitors of purified human topoisomerase IIalpha , whereas the ring-saturated analog succinimide was completely inactive. Catalytic inhibition was not abrogated by topoisomerase II mutations that totally abolish the effect of bisdioxopiperazine compounds on catalytic inhibition, suggesting a different mode of action by these maleimides. Furthermore, in DNA cleavage assay maleimide and NEM could antagonize etoposide-induced DNA double-strand breaks. Consistently, maleimide could antagonize the effect of topoisomerase II poisons in three different in vivo assays: 1) In an alkaline elution assay maleimide protected against etoposide-induced DNA damage. 2) In a band depletion assay maleimide reduced etoposide-induced trapping of topoisomerase IIalpha and beta  on DNA. 3) In a clonogenic assay maleimide antagonized the cytotoxicity of etoposide and daunorubicin on four different cell lines of human and murine origin. at-MDR cell lines with reduced nuclear topoisomerase IIalpha content are fully sensitive to maleimide, indicating that it is not a topoisomerase II poison in vivo. Our finding that topoisomerase II is sensitive to maleimide, NMM, and NEM but insensitive to succinimide demonstrates a strict requirement for the unsaturated ring bond for activity. We suggest that the observed antagonism in vitro and in vivo is caused by covalent modification of topoisomerase II cysteine residues reducing the amount of catalytically active enzyme sensitive to the action of topoisomerase II poisons.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
M. Grauslund, A. V. Thougaard, A. Fuchtbauer, K. F. Hofland, P. H. Hjorth, P. B. Jensen, M. Sehested, E.-M. Fuchtbauer, and L. H. Jensen
A Mouse Model for Studying the Interaction of Bisdioxopiperazines with Topoisomerase II{alpha} in Vivo
Mol. Pharmacol., October 1, 2007; 72(4): 1003 - 1014.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
L. H. Jensen, H. Liang, R. Shoemaker, M. Grauslund, M. Sehested, and B. B. Hasinoff
A Three-Dimensional Quantitative Structure-Activity Relationship Study of the Inhibition of the ATPase Activity and the Strand Passing Catalytic Activity of Topoisomerase II{alpha} by Substituted Purine Analogs
Mol. Pharmacol., November 1, 2006; 70(5): 1503 - 1513.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. P. Swift, A. Rephaeli, A. Nudelman, D. R. Phillips, and S. M. Cutts
Doxorubicin-DNA Adducts Induce a Non-Topoisomerase II-Mediated Form of Cell Death.
Cancer Res., May 1, 2006; 66(9): 4863 - 4871.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. H. Jensen, A. V. Thougaard, M. Grauslund, B. Sokilde, E. V. Carstensen, H. K. Dvinge, D. A. Scudiero, P. B. Jensen, R. H. Shoemaker, and M. Sehested
Substituted Purine Analogues Define a Novel Structural Class of Catalytic Topoisomerase II Inhibitors
Cancer Res., August 15, 2005; 65(16): 7470 - 7477.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
B. B. Hasinoff, X. Wu, O. V. Krokhin, W. Ens, K. G. Standing, J. L. Nitiss, T. Sivaram, A. Giorgianni, S. Yang, Y. Jiang, et al.
Biochemical and Proteomics Approaches to Characterize Topoisomerase II{alpha} Cysteines and DNA as Targets Responsible for Cisplatin-Induced Inhibition of Topoisomerase II{alpha}
Mol. Pharmacol., March 1, 2005; 67(3): 937 - 947.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Renodon-Corniere, T. K. Sorensen, P. B. Jensen, J. L. Nitiss, B. Sokilde, M. Sehested, and L. H. Jensen
Probing the Role of Linker Substituents in Bisdioxopiperazine Analogs for Activity against Wild-Type and Mutant Human Topoisomerase IIalpha
Mol. Pharmacol., May 1, 2003; 63(5): 1159 - 1168.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics